Intravenous immune globulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is a product made up of human antibodies that can be given intravenously (through a vein) . IVIG is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. IVIG is used to manage various immunodeficiency states and a plethora of other conditions, including autoimmune, infectious, and inflammatory states. It is also used for certain rheumatologic diseases including Kawasaki’s disease in children, inflammatory muscle diseases, and very low platelet counts in those with systemic lupus erythematosus. IVIG is given as an intravenous infusion (through the vein in the arm), which takes several hours to complete. The frequency and duration of infusions depend on the underlying disease and the clinical course. IVIG can take several weeks to fully take effect. Patients receiving initial (first-time) IVIG infusions and high-risk categories should be monitored carefully for any infusion-related reactions or adverse effects.